Loading...
XSHE
000908
Market cap961mUSD
Dec 05, Last price  
7.73CNY
1D
-5.04%
1Q
29.05%
Jan 2017
-26.03%
Name

Hunan Jingfeng Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:000908 chart
P/E
44.65
P/S
16.35
EPS
0.17
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
-20.91%
Revenues
416m
-36.67%
214,423,001237,627,852187,731,103216,801,752236,376,147217,389,628139,030,825145,267,112167,307,8851,957,430,0132,459,038,6812,640,503,6292,583,652,3352,585,696,9011,344,029,111877,918,599811,183,491840,657,161656,893,837416,031,777
Net income
152m
P
2,973,7102,728,1495,653,952002,991,727003,369,095251,029,269324,101,704340,028,576162,085,589186,812,6600000-215,144,077152,304,308
CFO
-6m
L
057,903,24152,264,93031,015,808000351,5010205,930,47092,367,54912,324,621151,650,408350,937,84536,170,4280123,834,599123,266,70135,063,943-5,550,958
Dividend
Aug 23, 20180.01 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Hunan Jingfeng Pharmaceutical Co.,Ltd. manufactures and sells chemical drugs and biological agents in China. The company's principal product is sodium hyaluronate injection for use in orthopedics and surgery applications. It also offers ophthalmology and API products, as well as engages in the research and development of anti-tumor, cancer, and cardiovascular drugs; and provides skin care products. The company was founded in 2003 and is headquartered in Shanghai, China.
IPO date
Feb 03, 1999
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT